



## Total Voting Rights

February 1, 2024 9:24 AM EST

RNS Number : 7033B

MaxCyte, Inc.

01 February 2024

MaxCyte, Inc.

("MaxCyte" or the "Company")

### Total Voting Rights

**ROCKVILLE, Maryland - 1 February 2024:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, since 31 December 2023 it has issued 48,561 of common stock, \$0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options and/or vesting of restricted stock units.

#### Total voting rights

As at 31 January 2024, the total issued stock capital of the Company following the recent issue of the new Common Stock is 104,010,231 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

For further information, please contact:

#### MaxCyte Contacts:

##### *US IR Adviser*

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

##### *Nominated Adviser and Joint Corporate*

##### *Broker*

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

##### *UK IR Adviser*

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-](mailto:maxcyte@consilium-)

[comms.com](http://comms.com)

#### About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy

sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](https://maxcyte.com) and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRQKDBBCBKDBK